Saturday 17 October 2026
Export MAIA’s income statement to Excel — free account
MAIA Biotechnology, Inc.
MAIA Healthcare Biotechnology
In the quarter to June 2026, EPS grew 27.8% and free cash flow fell 63.2%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
1.10
0.02
−1.79%
Follow MAIA
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | — | 3.10 | 0.82 | 0.99 | 0.87 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | — | 9.64 | 5.22 | 5.99 | 2.74 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | 12 | 18 | 13 | 13 | 13 | ||||
| Revenue/emp, $m | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | ||||
| Gross margin, % | — | — | — | — | — | — | — | — | — | — | |||||
| EBT | — | — | — | (7) | (7) | (13) | (16) | (20) | (23) | (22) | |||||
| EBT margin, % | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Net income | — | — | — | (6) | (7) | (13) | (16) | (20) | (23) | (22) | |||||
| Depreciation | — | — | — | — | — | 1 | — | — | — | — | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Earnings | — | — | — | (0.61) | (0.62) | (2.37) | (1.75) | (1.49) | (1.05) | (0.70) | |||||
| Cash flow | — | — | — | (0.15) | (0.17) | (0.78) | (1.30) | (0.99) | (0.71) | (0.59) | |||||
| Capex | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Free cash flow | — | — | — | (0.15) | (0.17) | (0.78) | (1.30) | (0.99) | (0.71) | (0.59) | |||||
| Book value | — | — | — | (0.02) | (0.31) | 1.74 | 0.92 | 0.04 | 0.16 | 0.07 | |||||
| Shares, m | — | — | — | 11 | 11 | 5 | 9 | 13 | 22 | 32 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | ||||
| P/S | — | — | — | — | — | — | — | — | — | — | |||||
| P/B | — | — | — | — | — | — | — | — | — | — | |||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | |||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | (2) | (2) | (4) | (12) | (13) | (16) | (19) | ||||
| Capex | — | — | — | — | — | — | — | — | — | — | |||||
| Free cash flow | — | — | — | (2) | (2) | (4) | (12) | (13) | (16) | (19) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | 1 | (1) | 9 | 9 | 3 | 6 | 4 | ||||
| Total debt | — | — | — | 0 | 1 | — | — | — | — | — | |||||
| Net debt | — | — | — | (2) | 0 | (11) | (11) | (7) | (10) | (9) | |||||
| Shareholders’ equity | — | — | — | 0 | (3) | 9 | 9 | 0 | 4 | 2 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | 0.00 | (535.00) | (207.13) | (138.93) | (201.88) | (262.44) | (225.54) | ||||
| ROIC | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| ROE | — | — | — | 0.00 | 378.27 | (427.84) | (183.39) | (440.12) | (1,131.04) | (745.24) | |||||
Negative figures in brackets.
Charts ten years each
MAIA Biotechnology, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| HRTX Heron Therapeutics, Inc. | $71.5M | — (loss-making) | — (loss-making) | +1.25% (above 0%: growing) | n/m | +78.75% (above 0%: growing) | 69.28% | (5.43%) | Compare |
| MNOV MediciNova, Inc. | $71.4M | — (loss-making) | — (loss-making) | +240.56% (above 0%: growing) | n/m | +16.75% (above 0%: growing) | 69.33% | (554.36%) | Compare |
| CGTX Cognition Therapeutics, Inc. | $69.7M | — (loss-making) | — | — | n/m | +45.35% (above 0%: growing) | 0.00% | 0.00% | Compare |
| MAIA MAIA Biotechnology, Inc. | $69.2M | — (loss-making) | — | — | n/m | −63.23% (below 0%: shrinking) | — | 0.00% | |
| CSBR Champions Oncology, Inc. | $66.7M | — (loss-making) | — (loss-making) | +8.84% (above 0%: growing) | n/m | −198.74% (below 0%: shrinking) | 50.54% | (2.69%) | Compare |
| OSTX OS Therapies Incorporated | $66.0M | — (loss-making) | — | — | n/m | −134.43% (below 0%: shrinking) | — | 0.00% | Compare |
| HYFT MindWalk Holdings Corp. | $66.0M | — (loss-making) | — (loss-making) | +19.37% (above 0%: growing) | n/m | +9.79% (above 0%: growing) | 58.58% | (159.86%) | Compare |
| NMAD Nomad Power Solutions, Inc. | $65.9M | — (loss-making) | — | — | n/m | −230.63% (below 0%: shrinking) | — | 0.00% | Compare |
| XBIT XBiotech Inc. | $65.9M | — (loss-making) | — (loss-making) | −93.33% (below 0%: shrinking) | n/m | +25.25% (above 0%: growing) | 0.00% | 0.00% | Compare |
| Median of peers | $66.3M | — | — | +8.84% | — | +13.27% | 54.56% | (1.34%) |
MAIA Biotechnology, Inc. (MAIA) key facts
- MAIA Biotechnology, Inc. (MAIA) is a Biotechnology company in the Healthcare sector, listed on NYSE American.
- As of October 16, 2026, MAIA traded at $1.10, a market capitalization of $69.2 million.
- Return on equity was −745.2% and debt-to-equity 0.00.